The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million
Medanta expanded its bed capacity by 20% during the year
The move signals a strategic pivot toward deeper integration between clinical leadership and medical technology developers
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
The target reach is of more than 30 million young people and caregivers across 21 countries
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
Global specialty pipeline accelerates growth
Subscribe To Our Newsletter & Stay Updated
